Status:
COMPLETED
To Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Volunteers
Lead Sponsor:
Daewoong Pharmaceutical Co. LTD.
Conditions:
Idiopathic Pulmonary Fibrosis
Eligibility:
MALE
20-55 years
Phase:
PHASE1
Brief Summary
An open label, 2-part, one-sequence, 3-period study to evaluate drug-drug interactions between DWN12088 and nebivolol or Paroxetine in healthy volunteers
Eligibility Criteria
Inclusion
- Healthy male adults aged ≥ 20 and ≤ 55 years at screening
- Subjects who voluntarily decided to participate in the study and provided written consent to follow study compliance requirements after receiving a detailed explanation on this study and fully understanding the information
Exclusion
- Subjects unable to have the standard meal provided at the study site
- Subjects who took (the day of taking the last dose) another investigational or bioequivalence study product within 180 days prior to the first dose
Key Trial Info
Start Date :
June 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 27 2021
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04888728
Start Date
June 30 2021
End Date
July 27 2021
Last Update
August 4 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Inje University Busan Paik Hospital
Busan, South Korea, 47397